FDA approves iDose TR from Glaukos for reduction of IOP in OAG or ocular hypertension
December 14th 2023iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission.
FDA waves red flag over eye drops for potential risk of eye infection
Patients who have signs or symptoms of an eye infection after using these products should talk to their health care provider or seek medical care immediately.
FDA approves faricimab-svoa for the treatment of retinal vein occlusion
October 27th 2023According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
Regeneron receives FDA approval for aflibercept injection 8mg for treatment of wet AMD, DME, DR
August 19th 2023According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.